PRAX – praxis precision medicines, inc. (US:NASDAQ)
Stock Stats
News
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.
Praxis Precision Medicines (PRAX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Praxis Precision Medicines (PRAX) was upgraded by Raymond James Financial, Inc. to "strong-buy".
Form 8-K Praxis Precision Medicin For: Apr 14
Form 8-K Praxis Precision Medicin For: Apr 06
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: VANGUARD GROUP INC
Form S-8 Praxis Precision Medicin
Form 10-K Praxis Precision Medicin For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.